Apr 16th, 11:00 AM - 2:00 PM

Evaluating the Bioavailability of Carbamazepine Using a Novel SNEDDS Formulation

Gina M. Mattes  
*Cedarville University*, GMattes@cedarville.edu

Zachary A. Wallace  
*Cedarville University*, zwallace@cedarville.edu

Derrick L. Chapman  
*Cedarville University*, dlichapman@cedarville.edu

Jinwon Byun  
*Cedarville University*, jbyun@cedarville.edu

Rebecca A. Kyper  
*Cedarville University*, rkyper@cedarville.edu

*See next page for additional authors*

Follow this and additional works at: [http://digitalcommons.cedarville.edu/research_scholarship_symposium](http://digitalcommons.cedarville.edu/research_scholarship_symposium)

Part of the *Pharmacy and Pharmaceutical Sciences Commons*

---

Presenters
Gina M. Mattes, Zachary A. Wallace, Derrick L. Chapman, Jinwon Byun, Rebecca A. Kyper, and Elisha R. Injeti
Effect of Particle Size on Bioavailability of Carbamazepine Administered as a Nanoemulsion

Jinwon Byun, Derrick Chapman, Rebecca Kyper, Gina Mattes, and Zachary Wallace | Dr. Elisha Injeti | Cedarville University

Introduction

- Carbamazepine (CBZ) is an anticonvulsant drug primarily used to treat epilepsy, bipolar disorder, trigeminal and glossopharyngeal neuralgia.
- CBZ is a lipophilic and poorly soluble drug with limited ability to diffuse across biological membranes.
- To increase its bioavailability, CBZ is formulated into specialized nanoemulsions called Self Nano-Emulsifying Drug Delivery Systems (SNEDDS).
- SNEDDS are isotropic mixtures of oil, surfactants and cosurfactants that form fine oil-in-water nanoemulsions upon mild agitation, followed by injection into aqueous media of gastrointestinal tract.
- SNEDDS have shown to reduce the particle size of CBZ molecules and improve its solubility and ability to cross the biological membranes1.
- However, the in-vivo bioavailability of CBZ in SNEDDS hasn’t been investigated.

Experimental Methods

- The study will be conducted as a randomized controlled crossover experiment utilizing a rat model.
- Sprague-Dawley rats (n=12) will be divided randomly into two groups of same size.
- One group will be administered CBZ in standard formulation and SNEDDS for other group.
- After administration, blood samples will be collected at 5, 10, 15, 20, 30, 45, 60, 90, and 120 minutes2.
- Tail vein incision method will be used to collect blood samples.
- Samples will be stored at -20°C until ready for analysis2.
- CBZ in blood samples will be analyzed by reversed phase High Performance Liquid Chromatography (HPLC).

Objective

- The objective of this study is to study the effect of particle size on in-vivo bioavailability of CBZ administered as SNEDDS compared to a standard formulation

Data Analysis

- An unpaired t-test will be used to compare the significance between the two sets of data.

Results and Conclusions

- Bioavailability is expected to increase due to the deceased particle size of SNEDDS formulation.
- Limitations include a small sample size which will lower statistical power of the results.

References